<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04948242</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-19/SEMICYUC</org_study_id>
    <nct_id>NCT04948242</nct_id>
  </id_info>
  <brief_title>Characteristics of Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (COVID-19)</brief_title>
  <acronym>GETCOV-2</acronym>
  <official_title>Epidemiologic, Clinical Characteristics and Risk Factors of Critical Ill Patients Admitted to the ICU for Severe Acute Respiratory Syndrome Coronavirus 2 Infection (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Joan XXIII de Tarragona.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sociedad Española de Medicina Intensiva,critica y unidades coronarias</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari Joan XXIII de Tarragona.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter observational, prospective cohort study that consisted of a large-scale data&#xD;
      source of hospital ICU admissions and patient-level clinical data in Spain.&#xD;
&#xD;
      The main objective is to develop a national database belonging to SEMICYUC (Spanish Society&#xD;
      of Critical Care) to describe epidemiological and clinical characteristics and risk factors&#xD;
      related to ICU mortality in critically ill patients admitted to ICU due to severe COVID-19 in&#xD;
      Spain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: A multicenter observational, prospective cohort study&#xD;
&#xD;
      Setting: Intensive Care Units&#xD;
&#xD;
      Subjects: Adult Critical patients admitted to ICU with severe community-acquired pneumonia&#xD;
      due to confirmed SARS CoV-2 infection (COVID-19).&#xD;
&#xD;
      Data Collection and Validation Data was obtained from a voluntary registry created by Spanish&#xD;
      Society of Intensive Care Medicine-SEMICYUC. All consecutive cases admitted to the ICU were&#xD;
      collected.&#xD;
&#xD;
      There were no patients excluded from the analysis that was enrolled to participating ICU and&#xD;
      met criteria.&#xD;
&#xD;
      Data were collected using a paper CRF (case Report Form). CRF collect and record all&#xD;
      protocol-required information, which is transcribed from patient source documents, such as&#xD;
      hospital records and laboratory reports during the patient's participation in the study.&#xD;
      Before being sent to the National Study Coordinator (AR) this data was de-identified (not&#xD;
      traceable to the patient) by removing the patient's name, medical record number, etc., and&#xD;
      giving the patient a unique study number. We implemented a double data entry model for&#xD;
      potential errors in real-time. Data was entered twice by two different Data Entry personnel&#xD;
      based on the same set of data collected in the paper CRFs. All data were reviewed, and values&#xD;
      that appeared incongruent or out of range were manually validated by confirming the accuracy&#xD;
      of the data with the Study Coordinator (AR). The database was validated and cleaned before&#xD;
      the statistical analysis and the study database was locked to prevent any further changes,&#xD;
      and to ensure data consistency and integrity for the statistical reporting and analysis.&#xD;
&#xD;
      Sample size calculation:&#xD;
&#xD;
      No statistical sample size calculation was performed a priori, and sample size was equal to&#xD;
      the number of patients admitted to the participant's ICUs with confirmed COVID-19 during the&#xD;
      study period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Epidemiologic and Clinical Characteristics and risk factors for ICU mortality in critically ill patients with COVID-19 in Spain</measure>
    <time_frame>Observational period from ICU admission to data of discharge alive or date of death from any cause at days 28 of ICU lenght of stay and ICU discharge</time_frame>
    <description>To determine demographics and clinical factors associated with ICU mortality at days-28 and ICU discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Support respiratory type and prognosis</measure>
    <time_frame>Observational period from ICU admission to data of discharge alive or date of death from any cause at days 28 of ICU lenght of stay and ICU discharge</time_frame>
    <description>Association between respiratory support used at ICU admission and ICU mortalily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comorbidities and prognosis</measure>
    <time_frame>Observational period from ICU admission to data of discharge alive or date of death from any cause at days 28 of ICU lenght of stay and ICU discharge</time_frame>
    <description>Association between different comorbidities (diabetes, obesity, hypertension, etc) and ICU mortality</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>SARS-CoV2 Infection</condition>
  <arm_group>
    <arm_group_label>Consecutive critically ill patients admitted to ICU with severe SARS-CoV-2 infection</arm_group_label>
    <description>Consecutive adult patients (&gt; 16 years) with laboratory confirmed SARS-CoV-2 infection, detected by RT-PCR positive test of nasopharyngeal, oropharyngeal , swab or invasive respiratory samples according to the WHO recommendations. The follow-up of patients was to ICU discharge or death whichever occurred first. No interventions will be made. Only anonymized demographic data, clinical data, laboratory data and ventilatory support data will be collected. There is no standardized pharmacological treatment protocol. Only basic data are collected about the different treatments administered by the attending physician.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill patients with community-acquired pneumonia due to SARS-CoV-2 infection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Severe community-acquired pneumonia due SARS CoV-2 infection and acute respiratory&#xD;
             failure with microbiological confirmation (RT-PCR) according international guidelines&#xD;
&#xD;
          2. Age &gt;= 16 years without upper limit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 16 years&#xD;
&#xD;
          2. Patients with SARS-CoV-2 infection without acute respiratory failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alejandro Rodriguez Oviedo, MD,PhD,MsC</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitari de Tarragona Joan XXIII</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alejandro Rodríguez Oviedo, MD,PhD,MsC</last_name>
    <phone>+34977295818</phone>
    <email>ahr1161@yahoo.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra Trefler Crespo, BsC,PhD</last_name>
    <phone>+34977295818</phone>
    <email>sitrefler@yahoo.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario de Tarragona Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <zip>43007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandro Rodríguez Oviedo, MD,PhD,MsC</last_name>
      <phone>+34977295818</phone>
      <email>ahr1161@yahoo.es</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Trefler Crespo, BsC,PhD</last_name>
      <phone>+34977295818</phone>
      <email>sitrefler@yahoo.es</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://semicyuc.org/covid-19/</url>
    <description>Spanisho Society of Critical Care web</description>
  </link>
  <reference>
    <citation>Berenguer J, Ryan P, Rodríguez-Baño J, Jarrín I, Carratalà J, Pachón J, Yllescas M, Arriba JR; COVID-19@Spain Study Group; Fundación SEIMC-GESIDA; Hospital General Universitario Gregorio Marañón; Hospital Universitario La Paz; Hospital Infanta Leonor; Complejo Hospitalario Virgen de la Salud; Hospital Universitario Rafael Méndez; Hospital Universitario de Cruces; Hospital de Melilla; Hospital San Eloy de Barakaldo; Hospital Universitario Central de Asturias; Hospital General Universitario de Alicante; Hospital Virgen de la Victoria; Hospital Universitario Puerto Real; EOXI Pontevedra e Salnés; Hospital de Figueres; Hospital Sant Jaume de Calella; Hospital del Mar; Hospital Virgen de la Arrixaca; Hospital de Can Misses; Hospital de Sagunto; Hospital Clínico San Cecilio; Hospital Universitario Príncipe de Asturias; Parc Sanitari Sant Joan de Déu; Hospital Nuestra Señora de Gracia; HC Marbella Internacional Hospital; Hospital La Princesa; Hospital Josep Trueta; Hospital Dos de Maig; Hospital Arnau de Vilanova-Lliria; Hospital General Universitario de Elche; Hospital Clínico Universitario de Valencia; Complejo Asistencial de Ávila; Hospital Comarcal de Alcañiz; Hospital Universitario Marqués de Valdecilla; Hospital Quiron-Salud de Torrevieja; Hospital Universitario Miguel Servet; SCIAS, Hospital de Barcelona; Fundación Hospital Universitario Alcorcón; Hospital Álvaro Cunqueiro; Complejo Asistencial Universitario de Salamanca; Hospital Universitario Severo Ochoa; Hospital CIMA-Sanitas; Hospital HLA Inmaculada; Hospital Universitario Rio Hortega; Hospital de Guadalajara; Hospital Universitario Infanta Sofía; Hospital Comarcal de Blanes; Hospital Universitari de Tarragona Joan XXIII; Hospital Universitario Basurto; Hospital Universitario de Canarias; Hospital Universitario de Gran Canaria Dr Negrín; Hospital Son Espases; Hospital Universitario de Móstoles; Complejo Hospitalario Universitario A Coruña; Hospital Costa del Sol; Hospital Clínico Universitario Lozano Blesa; Hospital Mutua de Terrassa; Hospital de la Plana; Hospital Virgen de la Concha-Complejo Asistencial de Zamora; Complejo Hospitalario Universitario Insular Materno-Infantil; Hospital de la Marina Baixa; Hospital Universitario Virgen Macarena; Hospital Universitari de Bellvitge; Hospital Universitario y Politécnico la Fe; Hospital Universitario del Vinalopó; Hospital de Sabadell (Parc Tauli); Hospital Clinic de Barcelona; Hospital Universitario de la Ribera; Fundación Jiménez Díaz; Hospital Clínico Universitario de Valladolid; Hospital Clínico San Carlos; Hospital Santa Creu i Sant Pau; Clínica Universitaria de Navarra-Campus Madrid; Hospital Son Llatzer; Hospital General de la Defensa Gómez Ulla; Hospital Universitario de Álava; Hospital Santos Reyes; Hospital Dr José Molina Orosa; Hospital Vall d'Hebrón; Hospital Universitario Rey Juan Carlos; Complejo Hospitalario Universitario Santa Lucía; Hospital Santa Bárbara; Complejo Hospitalario Universitario de Ferrol; Hospital de l'Esperit Sant; Hospital Universitario los Arcos del Mar Menor; Hospital HLA Universitario Moncloa; Hospital Virgen del Puerto; Hospital Marina Salud de Dénia; Hospital Universitario de Jerez; Hospital Reina Sofía de Tudela; Hospital Clínico Universitario de Santiago de Compostela; Hospital Universitario del Henares; Hospital Universitario Lucus Augusti; Hospital de Donostia; Hospital de Urduliz Alfredo Espinosa; Hospital de Mendaro; Hospital Juan Ramón Jiménez; Hospital de Tortosa Virgen de la Cinta; Hospital Riotinto; Hospital Vega Baja; Hospital Puerta de Hierro; Hospital Universitario de Getafe; Hospital General de la Palma; Hospital El Bierzo; Fundación Hospital de Calahorra; Hospital Alto Deba; Hospital Universitario San Juan de Alicante; Hospital de Guadarrama; Hospital Universitario de Jaén; Hospital de Mataró; Hospital de Palamós; Hospital Universitario de Valme; Clínica Universitaria de Navarra-Campus Navarra; Hospital Clínica Benidorm; Hospital Doce de Octubre; Hospital Universitario Virgen del Rocío; Hospital Universitario Ramón y Cajal; Hospital Universitario San Pedro; Hospital Quirón A Coruña; HM Sanchinarro; Hospital Francesc de Borja; Complejo Hospitalario Universitario Nuestra Señora de La Candelaria; Hospital Universitario HM Montepríncipe; Hospital Universitario HM Puerta del Sur; Hospital Universitario HM Torrelodones; Hospital Universitario HM Madrid; Hospital Don Benito-Villanueva de la Serena; Hospital de Viladecans; Centro Nacional de Epidemiología. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect. 2020 Nov;26(11):1525-1536. doi: 10.1016/j.cmi.2020.07.024. Epub 2020 Aug 4.</citation>
    <PMID>32758659</PMID>
  </reference>
  <reference>
    <citation>Berenguer J, Borobia AM, Ryan P, Rodríguez-Baño J, Bellón JM, Jarrín I, Carratalà J, Pachón J, Carcas AJ, Yllescas M, Arribas JR; COVID-19@Spain and COVID@HULP Study Groups. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. Thorax. 2021 Sep;76(9):920-929. doi: 10.1136/thoraxjnl-2020-216001. Epub 2021 Feb 25.</citation>
    <PMID>33632764</PMID>
  </reference>
  <results_reference>
    <citation>Rodríguez A, Ruiz-Botella M, Martín-Loeches I, Jimenez Herrera M, Solé-Violan J, Gómez J, Bodí M, Trefler S, Papiol E, Díaz E, Suberviola B, Vallverdu M, Mayor-Vázquez E, Albaya Moreno A, Canabal Berlanga A, Sánchez M, Del Valle Ortíz M, Ballesteros JC, Martín Iglesias L, Marín-Corral J, López Ramos E, Hidalgo Valverde V, Vidaur Tello LV, Sancho Chinesta S, Gonzáles de Molina FJ, Herrero García S, Sena Pérez CC, Pozo Laderas JC, Rodríguez García R, Estella A, Ferrer R; COVID-19 SEMICYUC Working Group. Deploying unsupervised clustering analysis to derive clinical phenotypes and risk factors associated with mortality risk in 2022 critically ill patients with COVID-19 in Spain. Crit Care. 2021 Feb 15;25(1):63. doi: 10.1186/s13054-021-03487-8.</citation>
    <PMID>33588914</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>June 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari Joan XXIII de Tarragona.</investigator_affiliation>
    <investigator_full_name>Alejandro Rodriguez Oviedo , MD</investigator_full_name>
    <investigator_title>MD,PhD,MsC</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Severe SARS-CoV-2 infection</keyword>
  <keyword>Critically ill patients</keyword>
  <keyword>ADRS</keyword>
  <keyword>Viral pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

